Multivalent vaccine composition with mixed carrier
The invention concerns a pharmaceutical composition for treating or preventing a certain number of infections caused by pathogenic agents such as bacteria, comprising as immunogen, one or several polyosides derived from one or several pathogenic agents. The polyosides are in the form of conjugates, coupled with a carrier protein. The composition contains at least two types of conjugates, each being at least characterised by a different protein carrier.
1. A method of immunizing a human against Streptococcus pneumoniae , the method comprising administering a vaccine composition comprising an effective dose of “n” conjugates C1 to Cn, wherein
(a) each conjugate comprises
(i) a polysaccharide S1 to Sn from a Streptococcus pneumoniae serotype/serogroup, respectively, and
(ii) a carrier protein P1 to Pn, respectively;
(b) “n” is a number equal to or greater than 10;
(c) the polysaccharides S1 to Sn are identical or there are from 2 to “n” different polysaccharides; and
(d) the carrier proteins P1 to Pn are selected independently from a group consisting of “m” carrier proteins, wherein “m” is a number equal to or greater than 2;
(e) at least one of P1 to Pn is Dt and at least one of P1 to Pn is Tt; and
(f) the amount of conjugated Dt protein is less than or equal to 60 μg/dose and the amount of conjugated Tt protein in the composition is less than or equal to 25 μg/dose.
2. The method according to claim 1 , in which the conjugates C1 to Cn are all different from each other either by their polysaccharide, by their carrier protein, or by their polysaccharide and their carrier protein.
3. The method according to claim 2 , in which the polysaccharides S1 to Sn are all different from each other.
4. The method according to claim 1 in which the carrier proteins P1 and Pn are independently selected from Dt and Tt.
5. The method according to claim 4 , in which when “n” is an even number, “n”/2 carrier proteins P1 to Pn are a first protein and “n”/2 carrier proteins P1 to Pn are a second protein or when “n” is an odd number, (“n”+1)/2 carrier proteins P1 to Pn are a first protein and (“n”−1)/2 carrier proteins P1 to Pn are a second protein.
6. The method according to claim 1 , which comprises 10 or 11 conjugates in which the polysaccharides S1 to Sn are all different from each other and are chosen from serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F of S. pneumoniae .
7. The method according to claim 6 , which comprises 10 or 11 conjugates selected from:
serotype 1 polysaccharide coupled to Tt or to Dt;
serotype 3 polysaccharide coupled to Dt;
serotype 4 polysaccharide coupled to Tt;
serotype 5 polysaccharide coupled to Tt or to Dt;
serotype 6B polysaccharide coupled to Dt;
serotype 7F polysaccharide coupled to Tt or to Dt;
serotype 9V polysaccharide coupled to Tt;
serotype 14 polysaccharide coupled to Dt;
serotype 18C polysaccharide coupled to Dt;
serotype 19F polysaccharide coupled to Tt; and
serotype 23F polysaccharide coupled to Tt.
8. The method according to claim 1 wherein n is 12 to 22 and the composition comprises 10 or 11 different polysaccharides S1 to Sn chosen from serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F and in which conjugates having the same polysaccharide differ from each other in the carrier protein.
9. The method according to claim 8 , which comprises:
serotype 1 polysaccharide coupled to Tt;
serotype 3 polysaccharide coupled to Dt;
serotype 4 polysaccharide coupled to Tt;
serotype 5 polysaccharide coupled to Tt;
serotype 6B polysaccharide coupled to Dt;
serotype 6B polysaccharide coupled to Tt;
serotype 7F polysaccharide coupled to Tt;
serotype 9V polysaccharide coupled to Tt;
serotype 9V polysaccharide coupled to Dt;
serotype 14 polysaccharide coupled to Dt;
serotype 18C polysaccharide coupled to Dt;
serotype 18C polysaccharide coupled to Tt;
serotype 19F polysaccharide coupled to Tt;
serotype 23F polysaccharide coupled to Tt; and
serotype 23F polysaccharide coupled to Dt.